Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL JAMES DOWNING

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1639159346
CMS profile
300554
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$626.73

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $626.73 20

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Sage Therapeutics, Inc. $325.00 5
Janssen Pharmaceuticals, Inc $104.32 4
Alkermes, Inc. $75.20 5
ITI, Inc. $39.20 2
AbbVie Inc. $37.62 2
Teva Pharmaceuticals USA, Inc. $26.15 1
Indivior Inc. $19.24 1

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL JAMES DOWNING

NPI 1639159346 · CMS profile ID 300554

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $626.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $32.6111/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102165 CMS
Teva Pharmaceuticals USA, Inc. $26.1511/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056789173 CMS
Alkermes, Inc. $13.9211/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808419 CMS
Indivior Inc. $19.2411/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034223069 CMS
Alkermes, Inc. $15.9609/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808417 CMS
Janssen Pharmaceuticals, Inc $24.9408/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102155 CMS
Alkermes, Inc. $14.7308/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808415 CMS
ITI, Inc. $25.5506/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040517805 CMS
Alkermes, Inc. $15.4206/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808413 CMS
Sage Therapeutics, Inc. $50.0006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017096065 CMS
Sage Therapeutics, Inc. $37.5006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017097227 CMS
Sage Therapeutics, Inc. $37.5006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017098319 CMS
Sage Therapeutics, Inc. $50.0006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017102035 CMS
Sage Therapeutics, Inc. $150.0006/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017104067 CMS
Janssen Pharmaceuticals, Inc $24.5105/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102187 CMS
ITI, Inc. $13.6504/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040517795 CMS
AbbVie Inc. $15.4203/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996737965 CMS
Alkermes, Inc. $15.1702/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808411 CMS
Janssen Pharmaceuticals, Inc $22.2602/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102175 CMS
AbbVie Inc. $22.2001/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996737959 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.48 15
PY2020 $163.49 9
PY2021 $551.28 27
PY2022 $399.89 22
PY2023 $626.73 20
PY2024 $647.99 23
PY2025 $847.36 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $914,450.61 88
PY2024 Recipient $2,949.66 2
PY2024 Principal investigator $1,362,460.91 98
PY2023 Recipient $59,611.81 14
PY2023 Principal investigator $997,596.68 181
PY2022 Principal investigator $897,046.39 115
PY2021 Principal investigator $714,455.57 113
PY2020 Principal investigator $1,352,717.69 219
PY2019 Recipient $157,177.13 20
PY2019 Principal investigator $1,373,636.72 268

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

100 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $400.00 12/31/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS
M23-714 Ubrelvy Menstrual Migraine No dispute reported 06/30/2026 1100765081
Principal investigator 1 Axsome Therapeutics, Inc. $43,479.53 12/30/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258307
Principal investigator 1 Axsome Therapeutics, Inc. $19,674.83 12/12/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258309
Principal investigator 1 Axsome Therapeutics, Inc. $22,948.15 11/30/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258305
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $5,375.70 11/27/2024 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211 No dispute reported 06/30/2026 1081189970
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,871.10 11/27/2024 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211 No dispute reported 06/30/2026 1081189972
Principal investigator 1 Axsome Therapeutics, Inc. $23,485.25 11/15/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258317
Principal investigator 1 Eli Lilly and Company $193.70 11/08/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137359755
Principal investigator 1 ABBVIE INC. $10,532.00 11/07/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1100753721
Principal investigator 1 Eli Lilly and Company $202.00 10/31/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137359801
Principal investigator 1 Axsome Therapeutics, Inc. $16,754.11 10/30/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258303
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $9,500.00 10/23/2024 Non-covered Recipient Entity
Futuresearch Trials Of Dallas Llc
LX9211 No dispute reported 06/30/2026 1081189812
Principal investigator 1 Eli Lilly and Company $797.01 10/17/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137359007
Principal investigator 1 Axsome Therapeutics, Inc. $23,526.30 10/16/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258319
Recipient Eli Lilly and Company $2,872.00 10/15/2024 Covered Recipient Physician A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137348593
Principal investigator 1 PFIZER INC. $864.26 09/12/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130909594
Principal investigator 1 Axsome Therapeutics, Inc. $31,405.79 09/10/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258315
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $403.00 09/06/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081189334
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $159.00 09/06/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081189336
Principal investigator 1 PFIZER INC. $2,800.00 09/05/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130907014
Principal investigator 1 PFIZER INC. $494.60 09/05/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130907983
Principal investigator 1 PFIZER INC. $1,100.00 09/05/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130909025
Principal investigator 1 PFIZER INC. $500.00 09/05/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130909183
Principal investigator 1 Eli Lilly and Company $3,040.51 09/04/2024 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137359105
Principal investigator 1 Boehringer Ingelheim International GmbH $3,896.25 09/01/2024 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
Phase II dose finding trial in monotherapy for MDD No dispute reported 06/30/2026 1101071341
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 08/30/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432972
Principal investigator 1 PFIZER INC. $800.00 08/29/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130905252
Principal investigator 1 PFIZER INC. $1,230.00 08/29/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130905256
Principal investigator 1 PFIZER INC. $1,599.00 08/29/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130905260
Principal investigator 1 PFIZER INC. $626.50 08/29/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130909044
Principal investigator 1 PFIZER INC. $3,000.00 08/22/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130908765
Principal investigator 1 Eli Lilly and Company $36,641.00 08/20/2024 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137359101
Principal investigator 1 Eli Lilly and Company $88,306.00 08/20/2024 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137359103
Principal investigator 1 PFIZER INC. $1,155.00 08/15/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130911518
Principal investigator 1 Axsome Therapeutics, Inc. $26,933.58 08/14/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258313
Principal investigator 1 Sumitomo Pharma America, Inc. $75.00 08/13/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432974
Principal investigator 1 Sumitomo Pharma America, Inc. $95.01 08/13/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432980
Principal investigator 1 Sumitomo Pharma America, Inc. $130.00 08/07/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432954
Principal investigator 1 Sumitomo Pharma America, Inc. $195.00 08/07/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432956
Principal investigator 1 Sumitomo Pharma America, Inc. $598.00 08/07/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432990
Principal investigator 1 ABBVIE INC. $3,850.00 08/05/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 1100735152
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 07/31/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432970
Principal investigator 1 Axsome Therapeutics, Inc. $17,535.06 07/30/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258297
Principal investigator 1 PFIZER INC. $992.51 07/25/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130908916
Recipient Eli Lilly and Company $77.66 07/17/2024 Covered Recipient Physician A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137349141
Principal investigator 1 Axsome Therapeutics, Inc. $37,916.13 07/16/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258311
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,207.00 07/12/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081189026
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $636.00 07/12/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081189048
Principal investigator 1 ABBVIE INC. $10,000.00 07/05/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1100728258
Principal investigator 1 Sumitomo Pharma America, Inc. $50.90 07/02/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432996
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 07/02/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148433004
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 07/02/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148433006
Principal investigator 1 Sumitomo Pharma America, Inc. $62.48 07/02/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148433008
Principal investigator 1 Sumitomo Pharma America, Inc. $33.70 07/02/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148433010
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,261.76 07/01/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 1101070523
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 06/28/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432968
Principal investigator 1 Sumitomo Pharma America, Inc. $31,883.40 06/24/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432988
Principal investigator 1 Axsome Therapeutics, Inc. $58,971.01 06/20/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258295
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $45,658.66 06/20/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
PoCC study in patients with PTSD No dispute reported 06/30/2026 1101073709
Principal investigator 1 PFIZER INC. $1,242.60 06/20/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130905233
Principal investigator 1 Sumitomo Pharma America, Inc. $50.90 06/04/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432994
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 06/04/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148433002
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 05/31/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432966
Principal investigator 1 PFIZER INC. $1,187.50 05/30/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1130907313
Principal investigator 1 PFIZER INC. $1,242.60 05/23/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130906509
Principal investigator 1 Sumitomo Pharma America, Inc. $40,532.40 05/17/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432976
Principal investigator 1 Axsome Therapeutics, Inc. $54,122.36 05/16/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258293
Principal investigator 1 PFIZER INC. $1,594.84 05/16/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130908769
Principal investigator 1 Sumitomo Pharma America, Inc. $55.28 05/02/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148433000
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 04/30/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432964
Principal investigator 1 PFIZER INC. $5,130.95 04/25/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1130906513
Principal investigator 1 PFIZER INC. $1,728.52 04/18/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130905709
Principal investigator 1 Axsome Therapeutics, Inc. $42,691.07 04/16/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258291
Principal investigator 1 Eli Lilly and Company $973.08 04/09/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137359011
Principal investigator 1 Eisai Inc. $13,556.36 04/08/2024 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1106529815
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 03/29/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432962
Principal investigator 1 PFIZER INC. $6,387.50 03/27/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1130905513
Principal investigator 1 PFIZER INC. $2,326.56 03/21/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130905520
Principal investigator 1 Axsome Therapeutics, Inc. $4,750.00 03/18/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258281
Principal investigator 1 Axsome Therapeutics, Inc. $37,556.42 03/18/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258287
Principal investigator 1 Axsome Therapeutics, Inc. $4,750.00 03/18/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258289
Principal investigator 1 Sumitomo Pharma America, Inc. $42,487.20 03/15/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432986
Principal investigator 1 Sumitomo Pharma America, Inc. $6.60 03/05/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432992
Principal investigator 1 Sumitomo Pharma America, Inc. $101.52 03/05/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148433012
Principal investigator 1 Axsome Therapeutics, Inc. $13,577.10 03/04/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258285
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 02/29/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432960
Principal investigator 1 Axsome Therapeutics, Inc. $13,577.12 02/25/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258279
Principal investigator 1 Axsome Therapeutics, Inc. $13,577.10 02/25/2024 Non-covered Recipient Entity
FutureSearch Trials of Dallas, LP
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148258283
Principal investigator 1 Eli Lilly and Company $7,744.25 02/21/2024 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137359345
Principal investigator 1 PFIZER INC. $2,980.15 02/15/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1130910161
Principal investigator 1 Sumitomo Pharma America, Inc. $1,454.27 02/14/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432978
Principal investigator 1 Sumitomo Pharma America, Inc. $16,005.60 02/14/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432984
Principal investigator 1 Eli Lilly and Company $1,572.48 02/12/2024 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF DALLAS LP
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137359005
Principal investigator 1 Sumitomo Pharma America, Inc. $138.20 02/01/2024 Non-covered Recipient Entity
FUTURESEARCH TRIAL DALLAS
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432998
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 01/31/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432958
Principal investigator 1 Sage Therapeutics, Inc. $266,683.27 01/29/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder No dispute reported 06/30/2026 1125013345
Principal investigator 1 Sumitomo Pharma America, Inc. $58,094.10 01/19/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148432982
Principal investigator 1 PFIZER INC. $8,971.71 01/18/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1130905509
Principal investigator 1 PFIZER INC. $7,057.55 01/18/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1130910414
Principal investigator 1 Sage Therapeutics, Inc. $83,940.66 01/02/2024 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 1125010924